Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-006498-49
    Sponsor's Protocol Code Number:21103
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2022-05-06
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-006498-49
    A.3Full title of the trial
    A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis
    Estudio de fase IIb pivotal para evaluar la eficacia y la seguridad de izokibep en sujetos con uveítis intermedia, posterior , no infecciosa o panuveítis
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis
    Estudio de izokibep en uveítis intermedia, posterior , no infecciosa o panuveítis
    A.4.1Sponsor's protocol code number21103
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorACELYRIN, INC.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportACELYRIN, INC.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationACELYRIN, INC.
    B.5.2Functional name of contact pointClinical Trial Information Desk
    B.5.3 Address:
    B.5.3.1Street Address23371 Mulholland Dr. PMB 417
    B.5.3.2Town/ cityWoodland Hills
    B.5.3.3Post codeCA 91364
    B.5.3.4CountryUnited States
    B.5.6E-mailclinicaltrials@acelyrin.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameIzokibep
    D.3.2Product code ABY-035
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIzokibep
    D.3.9.1CAS number 2226130-02-3
    D.3.9.2Current sponsor codeABY-035
    D.3.9.3Other descriptive nameRecombinant protein comprising two IL-17A binding domains and an albumin binding domain
    D.3.9.4EV Substance CodeSUB201240
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number80
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Non-infectious, Intermediate-, Posterior- or Pan-uveitis
    Uveítis intermedia, posterior ,no infecciosa o panuveítis
    E.1.1.1Medical condition in easily understood language
    Uveitis
    Uveítis
    E.1.1.2Therapeutic area Diseases [C] - Eye Diseases [C11]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 22.1
    E.1.2Level LLT
    E.1.2Classification code 10022557
    E.1.2Term Intermediate uveitis
    E.1.2System Organ Class 100000004853
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10036370
    E.1.2Term Posterior uveitis
    E.1.2System Organ Class 100000004862
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10033687
    E.1.2Term Panuveitis
    E.1.2System Organ Class 100000004853
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate that izokibep is efficacious compared to placebo, as measured by time to treatment failure occurring at or after week 10 and up to week 52
    Demostrar la eficacia de izokibep en comparación con el placebo, medida mediante el tiempo hasta el fracaso terapéutico ocurrido en la semana 10 o posteriormente y hasta la semana 52.
    E.2.2Secondary objectives of the trial
    - To demonstrate that izokibep is efficacious, as measured by:
    • Proportion of subjects that achieve quiescence at week 10
    • Change in BCVA from best state achieved ≤ week 10 to week 24
    • Change in the NEI VFQ-25 score from best state achieved ≤ week 10 to week 24
    • Change in central retinal thickness (by SD-OCT) from baseline to week 10
    • Change in central retinal thickness (by SD-OCT) from best state achieved ≤ week 10 up to week 52
    -To assess the safety and tolerability of izokibep as measured by the incidence of TEAEs, events of special interest, SAEs and clinically significant lab values and vital signs
    - To assess the immunogenicity of izokibep as measured by the presence of treatment-emergent ADAs
    -Demostrar la eficacia de izokibep, medida mediante:
    • La proporción de sujetos que logran la inactividad en la semana 10
    • El cambio en la MAVC desde el mejor estado logrado ≤ semana 10 hasta la semana 24
    • El cambio en la puntuación del NEI VFQ-25 respecto al mejor estado logrado ≤ semana 10 hasta la semana 24
    • El cambio en el espesor de la zona central de la retina (mediante TCO-DE) desde el inicio hasta la semana 10
    • El cambio en el espesor de la zona central de la retina (mediante TCO-DE) respecto al mejor estado logrado ≤ semana 10 hasta la semana 52
    - Evaluar la seguridad y la tolerabilidad de izokibep, medidas por la incidencia de AAST, acontecimientos de especial interés, AAG y valores analíticos y constantes vitales clínicamente significativos
    - Evaluar la inmunogenicidad de izokibep medida por la presencia de AAF durante el tratamiento
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Subject(male and female) must be ≥ 18 and ≤ 75 years of age
    - Subject is diagnosed with non-infectious intermediate-, posterior- or pan-uveitis
    - Active disease defined by the presence of at least 1 of the following criteria in at least 1 eye despite treatment with stable doses of corticosteroids for at least 2 weeks prior to day 1:
    o Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion by dilated indirect ophthalmoscopy, fundus photography, fluorescein angiography (FA), and Spectral-Domain Optical Coherence Tomography (SD-OCT) to determine whether a lesion is active or inactive (the central reading center assessment using FA, fundus photography and/or SD-OCT is required to confirm eligibility prior to day 1).
    o ≥ 2+ vitreous haze (National Eye Institute [NEI]/Standardization of Uveitis Nomenclature [SUN] criteria) by digital indirect ophthalmoscope and fundus photography (the central reading center assessment using fundus photography is required to confirm eligibility prior to day 1).
    - Currently receiving treatment with oral corticosteroids (≥ 7.5 mg/day to ≤ 40 mg/day oral prednisone/prednisolone or corticosteroid equivalent) at a stable dose for at least 2 weeks prior to day 1.
    - No known history of active tuberculosis (TB).
    - Subject has a negative TB test at screening,
    - Male and Female participants of childbearing potential must use effective methods of contraception

    For a complete overview of the inclusion criteria refer to the protocol.
    - El sujeto (hombres y mujeres) debe tener ≥18 años y ≤75 años
    - El sujeto cuenta con un diagnóstico de uveítis intermedia, posterior, no infecciosa o panuveítis
    - Enfermedad activa definida por la presencia de al menos 1 de los siguientes criterios en al menos 1 ojo pese al tratamiento con dosis estables de corticoesteroides durante al menos 2 semanas antes del día 1:
    o Lesión vascular inflamatoria, coriorretiniana y/o inflamatoria retiniana activa observada mediante oftalmoscopia indirecta con dilatación, fotografía del fondo de ojo, angiografía con fluoresceína (AF) y tomografía de coherencia óptica de dominio espectral (TCO-DE) para determinar si una lesión está activa o inactiva (la evaluación del centro de lectura centralizada mediante la AF, la fotografía del fondo de ojo y/o la TCO-DE es necesaria para confirmar la elegibilidad antes del día 1).
    o Neblina vítrea ≥2+ (criterios NEI/SUN) según oftalmoscopio indirecto digital y fotografía del fondo de ojo (la evaluación del centro de lectura centralizada mediante fotografía del fondo de ojo es necesaria para confirmar la elegibilidad antes del día 1).
    - Sujetos que estén recibiendo actualmente tratamiento con corticoesteroides orales (≥7,5 mg/día a ≤40 mg/día de prednisona/prednisolona oral o equivalente en corticoesteroides) a una dosis estable durante al menos 2 semanas antes del día 1.
    - Sin antecedentes conocidos de tuberculosis (TB) activa.
    - El sujeto presenta un resultado negativo en la prueba de TB en la selección
    - Los participantes de sexo masculino y femenino en edad fértil deben utilizar métodos anticonceptivos eficaces

    Para más información, consultar la lista completa en el protocolo de los criterios de inclusión
    E.4Principal exclusion criteria
    - Subject with isolated anterior uveitis
    - Subject with serpiginous choroidopathy
    - Subject with confirmed or suspected infectious uveitis
    - Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the study
    - Planned (elective) eye surgery during the course of the study
    - History of prior refractive laser surgery, laser surgery of the macula (including photodynamic therapy or focal laser photocoagulation), retinal laser photocoagulation, or neodymium-doped yttrium aluminum garnet posterior capsulotomy ≤ 30 days before day 1
    - History of any other prior ocular surgery ≤ 3 months prior to day 1 except surgery for cosmetic reasons that is not expected to impact vision
    - Subject with intraocular pressure of ≥ 25 mmHg while on ≥ 2 glaucoma medications or evidence of glaucomatous optic nerve injury
    - Subject with severe vitreous haze that precludes visualization of the fundus prior to first dose of study drug
    - Subject has a contraindication for mydriatic eye drops OR subject cannot be dilated sufficiently well to permit good fundus visualization
    - Subject with BCVA < 20 letters (Early Treatment Diabetic Retinopathy Study [ETDRS]) in at least 1 eye prior to first dose of study drug
    - Subject with proliferative or severe non-proliferative retinopathy or clinically significant macular edema due to diabetic retinopathy
    - Subject with neovascular/wet age-related macular degeneration
    - Subject with an abnormality of the vitreo-retinal interface (eg, vitreomacular traction, epiretinal membranes) with the potential for macular structural damage independent of the inflammatory process
    - Subject with a history of active scleritis ≤ 12 months of first dose of study drug
    - Active IBD within 3 years prior to enrollment
    - Active infection or history of infection
    - Candida infection requiring systemic treatment ≤ 3 months prior to first dose of study drug
    - Uncontrolled, clinically significant system disease such as diabetes mellitus, hypertension, cardiovascular disease including moderate to severe heart failure (New York Heart Association class III/IV), moderate to severe renal disease, moderate to severe liver disease, as determined by investigator
    - History of demyelinating disease (including myelitis) or neurological symptoms suggestive of demyelinating disease
    - Malignancy within 5 years
    - History or evidence of any clinically significant disorder, condition, or disease that, in the opinion of the investigator, may pose a risk to subject safety or interfere with the study evaluation, procedures or completion
    - Tuberculosis or fungal infection seen on available chest x-ray taken ≤ 3 months of screening or at screening (Exception: documented evidence of completed treatment and clinically resolved)
    - Known history of human immunodeficiency virus (HIV).
    - Prior exposure to biologics that had a potential or known association with progressive multifocal leukoencephalopathy (ie, natalizumab [Tysabri®], rituximab [Rituxan®] or efalizumab [Raptiva®])
    - Exposure to TNF-α inhibitors, IL-1, IL-12, IL-23, IL-12/23 receptor inhibitors or Janus kinase inhibitors within 5 half-lives prior to first dose of study drug
    - Positive hepatitis B surface antigen (HBsAg) or detected sensitivity on the hepatitis B virus DNA polymerase chain reaction (PCR) qualitative test for hepatitis B core antibody (HBcAb)/hepatitis B surface antibody (HBsAb) positive subjects OR positive hepatitis C virus antibody test at screening
    - A positive test for syphilis at screening
    - Laboratory abnormalities at screening

    For a complete overview of the exclusion criteria refer to the protocol.
    - Sujeto con uveítis anterior aislada
    - Sujeto con coroidopatía serpiginosa
    - Sujeto con uveítis infecciosa confirmada o sospechada
    - Sujeto con opacidad de la córnea o del cristalino que impida la visualización del fondo de ojo o que probablemente requiera cirugía de cataratas durante la duración del estudio
    - Cirugía ocular programada durante el transcurso del estudio
    - Antecedentes de cirugía refractiva con láser previa, cirugía con láser de la mácula (incluido el tratamiento fotodinámico o la fotocoagulación con láser focal), fotocoagulación con láser de la retina o capsulotomía posterior mediante láser de granate de itrio y aluminio con dopaje de neodimio ≤30 días antes del día 1
    - Antecedentes de cualquier otra cirugía ocular previa ≤3 meses antes del día 1, excepto cirugía por motivos estéticos sin previsión de afectar a la visión
    - Sujeto con presión intraocular ≥25 mm Hg mientras recibe ≥2 medicamentos para el glaucoma o evidencia de lesión glaucomatosa del nervio óptico
    - Sujeto con neblina vítrea grave que impida la visualización del fondo de ojo antes de la primera dosis del fármaco del estudio
    - El sujeto tiene una contraindicación para el colirio midriático O el sujeto no puede someterse a una dilatación lo suficientemente buena como para permitir una buena visualización del fondo del ojo
    - Sujeto con MAVC <20 letras (estudio de tratamiento temprano de la retinopatía diabética [ETDRS]) en al menos 1 ojo antes de la primera dosis del fármaco del estudio
    - Sujeto con retinopatía proliferativa o no proliferativa grave o edema macular clínicamente significativo debido a retinopatía diabética
    - Sujeto con degeneración macular relacionada con la edad neovascular/húmeda
    - Sujeto con una anomalía de la interfaz vitreorretiniana (p. ej., tracción vitreomacular, membranas epirretinianas) con posibilidad de daño estructural macular independiente del proceso inflamatorio
    - Sujeto con antecedentes de escleritis activa ≤12 meses antes de la primera dosis del fármaco del estudio
    - EII activa en un plazo de 3 años antes de la inscripción
    - Infección activa o antecedentes de infección
    - Infección por cándida que haya requerido tratamiento sistémico ≤3 meses antes de la primera dosis del fármaco del estudio
    - Enfermedad sistémica clínicamente significativa no controlada, como diabetes mellitus, hipertensión, enfermedad cardiovascular, incluida la insuficiencia cardíaca de moderada a grave (clase III/IV de la New York Heart Association), nefropatía de moderada a grave, hepatopatía de moderada a grave, según lo determinado por el investigador
    - Antecedentes de enfermedad desmielinizante (incluida la mielitis) o síntomas neurológicos indicativos de enfermedad desmielinizante
    - Neoplasia maligna en los últimos 5 años
    - Antecedentes o indicios de cualquier trastorno, afección o enfermedad clínicamente significativa que, en opinión del investigador, pueda suponer un riesgo para la seguridad del sujeto o interferir en la evaluación, los procedimientos o la finalización del estudio
    - Tuberculosis o micosis observada en la radiografía de tórax disponible, obtenida ≤3 meses antes de la selección o en la selección (excepción: evidencia documentada de tratamiento completado y resolución clínica)
    - Antecedentes conocidos de infección por el virus de la inmunodeficiencia humana (VIH)
    - Exposición previa a productos biológicos que tengan una asociación conocida o una posible asociación a la leucoencefalopatía multifocal progresiva (p. ej., natalizumab [Tysabri®], rituximab [Rituxan®] o efalizumab [Raptiva®])
    - Exposición a inhibidores del TNF-α, inhibidores de los receptores de IL-1, IL-12, IL-23, IL-12/23 o inhibidores de la cinasa Jano en las 5 semividas previas a la primera dosis del fármaco del estudio
    - Resultado positivo para el antígeno de superficie del virus de la hepatitis B (HBsAg) o sensibilidad detectada en la prueba cualitativa de reacción en cadena de la polimerasa (PCR) del ADN del virus de la hepatitis B en el caso de los sujetos positivos para anticuerpos contra el núcleo del virus de la hepatitis B (HBcAb)/anticuerpos de superficie del virus de la hepatitis B (HBsAb) O resultado positivo en la prueba de anticuerpos contra el virus de la hepatitis C en la selección
    - Prueba de sífilis con resultado positivo en la selección
    - Anomalías analíticas en la selección

    Para más información, consultar la lista completa en el protocolo de los criterios de exclusión
    E.5 End points
    E.5.1Primary end point(s)
    Time to treatment failure
    Tiempo hasta el fracaso terapéutico
    E.5.1.1Timepoint(s) of evaluation of this end point
    At any visit /time to treatment failure
    En cualquier visita/tiempo hasta el fracaso del tratamiento
    E.5.2Secondary end point(s)
    - Quiescence
    - BCVA
    - NEI VFQ-25
    - Central retinal thickness
    - TEAEs, events of special interest and SAEs
    - Laboratory values and vital signs
    - ADAs
    - Inactividad
    - MAVC
    - Puntuación del NEI VFQ-25
    - Espesor de la zona central de la retina
    - AAST, acontecimientos de especial interés y AAG
    - Valores analíticos y constantes vitales
    - AAF
    E.5.2.1Timepoint(s) of evaluation of this end point
    - Quiescence at week 10
    - BCVA from best state achieved ≤ week 10 to week 24
    - NEI VFQ-25 score from best state achieved ≤ week 10 to week 24
    - Central retinal thickness (by SD-OCT) from baseline to week 10
    - Central retinal thickness (by SD-OCT) from best state achieved ≤ week 10 up to week 52
    From start to end of study:
    - Incidence of TEAEs, events of special interest, SAEs
    - Laboratory values and vital signs at collected timepoints
    - ADAs
    - Inactividad en la semana 10
    - MAVC desde el mejor estado logrado ≤ semana 10 hasta la semana 24
    - Puntuación del NEI VFQ-25 respecto al mejor estado logrado ≤ semana 10 hasta la semana 24
    - Espesor de la zona central de la retina (mediante TCO-DE) desde el inicio hasta la semana 10
    - Espesor de la zona central de la retina (mediante TCO-DE) respecto al mejor estado logrado ≤ semana 10 hasta la semana 52
    Desde el inicio hasta el final del estudio:
    - AAST, acontecimientos de especial interés y AAG
    - Valores analíticos y constantes vitales en los puntos temporales de recogida
    - AAF
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Immunogenecity
    Inmunogenecidad
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned11
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA35
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    Austria
    France
    Spain
    Czechia
    Germany
    Italy
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    UVUP
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months11
    E.8.9.1In the Member State concerned days21
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months11
    E.8.9.2In all countries concerned by the trial days21
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 91
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 9
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 61
    F.4.2.2In the whole clinical trial 100
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    There is no plan to continue access to study drug after the end of study. The choice of further therapy for non-infectious, intermediate-, posterior- or pan-uveitis at the end of the clinical study depends on the patient's individual needs and is left at the physician's discretion, based on available therapies approved for such use.
    No está previsto continuar el acceso al fármaco del estudio después de su finalización. La elección de una terapia adicional para la uveítis no infecciosa, intermedia, posterior o pan-uveítis al final del estudio clínico depende de las necesidades individuales del paciente y se deja a la discreción del médico, basándose en las terapias disponibles aprobadas para tal uso.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2023-04-12
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2023-04-11
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 05:58:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA